Is the sequence of salmeterol (SM) and fluticasone p. (FP) dry powder inhalation crucial in persistent mild asthma?

R. W. Dal Negro, C. Micheletto, S. Tognella, F. Trevisan, C. Pomari (Bussolengo, Italy)

Source: Annual Congress 2002 - Asthma - Therapy and management -2
Session: Asthma - Therapy and management -2
Session type: Thematic Poster Session
Number: 396
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. W. Dal Negro, C. Micheletto, S. Tognella, F. Trevisan, C. Pomari (Bussolengo, Italy). Is the sequence of salmeterol (SM) and fluticasone p. (FP) dry powder inhalation crucial in persistent mild asthma?. Eur Respir J 2002; 20: Suppl. 38, 396

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009


A comparison of salmeterol xinafoate (SX) plus beclomethasone dipropionate (BDP) and theophylline (Theo) plus BDP in the treatment of moderate chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2005; 26: Suppl. 49, 292s
Year: 2005

Effect of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) on risk of severe exacerbations in asthma
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 260s
Year: 2004

A comparison of salmeterol xinafoate (SX) plus fluticasone propionate (FP) and slow-release theophylline (Theo) plus FP in the treatment of stable chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2006; 28: Suppl. 50, 31s
Year: 2006

The combination salmeterol (S) + fluticasone propionate (F) in mild-to-moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001

Salmeterol/fluticasone 50/100 (SFC) dry powder inhaler (DPI) provides improved control and quality of life in patients symptomatic on inhaled corticosteroids (ICS)
Source: Eur Respir J 2002; 20: Suppl. 38, 47s
Year: 2002

"Stepping down" in mild-to-moderate asthmatic children, being well controlled while receiving low doses of inhaled corticosteroids (ICS): nedocromil sodium (NS) vs. fluticasone propionate (FP) 100 mcg/day given either twice
Source: Eur Respir J 2006; 28: Suppl. 50, 713s
Year: 2006

In vivo dose response relation of inhaled fluticasone propionate (FP), adults with bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 132s
Year: 2004

Efficacy and safety of the new beclomethasone dipropionate/formoterol combination (HFA MDI) vs. budesonide/formoterol (DPI) in moderate to severe persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 434s
Year: 2006

Control of airway inflammation is maintained in asthma patients following a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC) compared with higher dose fluticasone propionate (FP) alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

Late Breaking Abstract - Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects.
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019



Effect of switching from high dose fluticasone propionate (FP) to FP/salmeterol (FSC) on airway inflammation in asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 44s
Year: 2004

Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

LATE-BREAKING ABSTRACT: TRINITY: A phase III study to compare the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) with tiotropium (Tio) and a free triple combination of BDP/FF (Foster®) + Tio in COPD patients
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016

Onset of action of salmeterol/fluticasone (SFC) in single inhaler vs. salmeterol (S) in patients with COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 285s
Year: 2003

A superior improvement in lung function in patients with moderate persistent asthma is seen with mometasone furoate 200 μg b.i.d delivered by dry powder inhaler compared with beclomethasone dipropionate 168 μg
Source: Eur Respir J 2001; 18: Suppl. 33, 96s
Year: 2001

Inhalation characteristics with Spiromax® (S) versus Turbuhaler® (T) dry powder inhalers (DPI) in healthy adults (HA) and in patients with asthma (A) or COPD
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013


Salmeterol/fluticasone combination product (SFC) provides better asthma control compared to high dose fluticasone (FP) in symptomatic patients with asthma
Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how?
Year: 2005


A comparison of the efficacy of beclomethasone dipropionate (BDP) and fluticasone propionate (FP) aqueous nasal spray on symptoms and quality of life in perennial allergic rhinitis
Source: Eur Respir J 2003; 22: Suppl. 45, 110s
Year: 2003